Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Pan African Resources cuts full-year guidance despite record first half

(Sharecast News) - Pan African Resources has scaled back its production guidance for the full year despite record output in the first half, but announced a new share buyback plan. The company said that a slower-than-expected ramp-up of the Evander underground subvertical shaft project, which is now fully commissioned and operational, and delays with at the Tennant Mines plant mean production will be 197,000oz for the 12 months to 30 June.

This is up 6% on last year but below the current guidance of 205,000oz to 215,000oz.

Nevertheless, for the second half, output was up 32% over the first half of the year at 112,000oz - a new record for the company.

Meanwhile, PAF reported a substantial reduction in gearing with net debt expected to fall to $155m by the end of the month, down 32% over just six months. "The group is expected to be fully degeared during FY26 at prevailing gold prices," it said.

The company also announced on Wednesday that the board has approved a $11.1m share buyback plan, starting next week.

"The Board believes that at the current Share price, the Company's Shares offer significant value, given the quality and profitability of the Group's existing operations and growth projects. The Board has therefore taken the decision to implement the Programme as part of the Company's broader strategy to deliver value to shareholders," PAF said.

Shares were down 1.5% at 46.8p by 1138 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.